Vaxcyte, INC Form 4 insider transactions

Vaxcyte Chief Operating Officer Jim Wassil sold 2,250 shares of common stock pursuant to a pre-arranged 10b5-1 trading plan.

Vaxcyte, Inc. reports a Form 4 filing detailing stock transactions by SVP, Finance & CAO Elvia Cowan, executed under a pre-arranged 10b5-1 trading plan.

Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported the sale of 2,250 shares of common stock, totaling approximately $131,000, executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's SVP of Finance and CAO, Elvia Cowan, sold 1,892 shares of common stock on March 17, 2026, through a pre-arranged 10b5-1 trading plan.

Vaxcyte's SVP of Finance and CAO, Elvia Cowan, reported significant equity transactions, including RSU grants and stock option exercises.

Vaxcyte's President and CFO, Andrew Guggenhime, reported the acquisition of restricted stock units and stock options, alongside shares disposed for tax obligations.

Vaxcyte CEO Grant Pickering reported significant equity transactions, including the acquisition of restricted stock units and stock options, alongside shares disposed for tax obligations.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, reported significant equity awards including restricted stock units and stock options.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported multiple equity transactions including RSU grants, stock option awards, and shares withheld for taxes.

Vaxcyte, Inc. CEO Grant Pickering reported a gift of 100,000 common shares to an irrevocable trust for estate planning purposes.

Vaxcyte President and CFO Andrew Guggenhime transferred 61,850 shares of common stock to a grantor retained annuity trust (GRAT) via ALG 2025 GRAT HOLDINGS LLC.

Vaxcyte, Inc. director Olivier Brandicourt was granted 1,357 restricted stock units and options to purchase 6,750 shares of common stock.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, sold 9,743 shares of common stock for approximately $46.69 per share under a pre-arranged trading plan.

Vaxcyte's SVP of Finance, Elvia Cowan, reported sales of common stock totaling 11,623 shares and a gift of 1,000 shares to a charitable fund.

Vaxcyte's SVP of Finance, Elvia Cowan, disposed of 482 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, disposed of 1,204 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the disposition of 4,422 shares of common stock through tax withholding and a divorce settlement.

Vaxcyte's President and CFO, Andrew Guggenhime, disposed of 2,890 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte, Inc. CEO Grant Pickering disposed of 7,356 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's SVP of Finance, Elvia Cowan, disposed of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, reported the surrender of shares to cover tax obligations related to RSU vesting.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the disposition of shares for tax obligations and a transfer related to a divorce settlement, alongside an acquisition through an employee stock plan.

Vaxcyte's President and CFO, Andrew Guggenhime, reported the surrender of shares to cover tax withholding obligations related to RSU vesting.

Vaxcyte CEO Grant Pickering reported the surrender of shares to cover tax withholding obligations related to RSU vesting, alongside updates to his beneficial ownership.

Vaxcyte's SVP of Finance, Elvia Cowan, reported the acquisition of restricted stock units and stock options as part of her compensation.

Vaxcyte, Inc. Director Olivier Brandicourt has reported the acquisition of 1,148 shares of common stock through restricted stock units and 5,807 stock options, effective June 12, 2025.

Vaxcyte, Inc. Director Halley E. Gilbert reported the acquisition of 3,041 restricted stock units and 15,372 stock options, alongside a transfer of previously held options, as detailed in a recent SEC Form 4 filing.

Vaxcyte, Inc. Director Teri Loxam was granted 3,041 Restricted Stock Units (RSUs) and options to purchase 15,372 shares of common stock, aligning her compensation with company performance.

Vaxcyte, Inc. Director Heath Lukatch was granted 3,041 restricted stock units and options to purchase 15,372 shares of common stock as part of his compensation.

Vaxcyte, Inc. Director John Furey received a grant of 3,041 restricted stock units and 15,372 stock options as part of his compensation.